Today's top medical abstracts
Oncology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Oncology
For Practicing
Oncologists
Conferences
Jobs
Newsletters
My Library
Topics in
Oncology
        Alternative Therapies
        Anemia/Polycythemia
        BMT/SCT
        Basic Science/Genetics
        Bone/Cartilage
        Breast
        Carcinogenesis
        Coagulation/Bleeding Dz
        Colorectal Cancer/Polyps
        Dermatologic Oncology
        Diagnostics/Radiology
        Economics of Medicine
        Endocrine Oncology
        GI Oncology
        Gynecologic Oncology
        Head and Neck
        Hepatobiliary/Pancreas
        Leukemia/Lymphoma
        Lung/Thoracic Oncology
        Myeloproliferative Dz
        Neurologic Oncology
        Pain/Palliative Care
        Pediatric Heme/Oncology
        Pharmacology/Therapy
        Popular Press
        Renal/Urologic
        Side Effects
        Soft Tissue/Sarcoma
        Transfusion Medicine
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Oncologists
Improving Your Bottom Line: Is Your Practice Prepared for a Disaster?
Owen Dahl, Owen Dahl Consulting
Today's Oncology News: MCF2, A New Mitotic Checkpoint Control Point
D Scott Cunningham MD, PhD, MDLinx Oncology
Clinical Trial Watch: Trial Points to Cancer-Fighting Potential of IL-7
Tracy Hampton, PhD, MDLinx Oncology
  See all
uterine sarcomas;adjuvant pelvic radiotherapy Article Summary

Print     Email This Article     Save in My Library   Free Abstract
Reed NS et al. - In a study to determine the role of post-operative radiation in the management of uterine sarcomas, it seems that prognostic factor analysis shows that stage, age, and histological subtype are important predictors of behaviour, which may explain differences between carcinosarcomas (CS) and leiomyosarcomas (LMS). CS appears to show more kinship to poorly differentiated endometrial carcinomas in behaviour

Methods
  • The study accrued 224 pts; all uterine sarcoma subtypes were permitted
  • Pts were required to have undergone as a minimum, TAH and BSO washings (166 pts) but nodal sampling was optional
  • There were 103 LMS, 91 CS, and 28 endometrial stromal sarcomas (ESS)
  • Pts were randomised to either observation or pelvic radiation, 51 Gy in 28 fractions over 5 weeks

Results
  • 112 were recruited to each arm
  • The initial analysis has shown a reduction in local relapse (14 vs 24) but no effect on either OS or PFS
  • No unexpected toxicity was seen in the radiation arm
  • No difference in either overall or disease-free survival was demonstrated but there is an increased local control for CS pts receiving radiation but without any benefit for LMS

 

--- DIAGNOSTICS/RADIOLOGY TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



 

--- GYNECOLOGIC ONCOLOGY TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



 

Sponsor
--- PHARMACOLOGY/THERAPY TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



Sponsor
Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.